North American Scientific to Hold Conference Call and Webcast on Second Quarter Fiscal Year 2008 Financial Results on Wednesday,
24 Giugno 2008 - 8:38PM
Business Wire
North American Scientific, Inc. (Nasdaq:NASM) announced today that
it will issue results for the second quarter of fiscal year 2008,
which ended April 30, 2008, at market close on Wednesday, June 25,
2008. The Company will host an investor conference call to review
its second quarter fiscal year 2008 financial results and latest
corporate developments, beginning at 1:30 p.m. PDT/4:30 p.m. EDT on
Wednesday, June 25, 2008. The dial-in number for the conference
call is 866-202-0886 for domestic participants and 617-213-8841 for
international participants, using the pass code 68823629. A taped
replay of the call will be available beginning approximately one
hour after the call�s conclusion and will remain available for
seven days. It can be accessed by dialing 888-286-8010 for domestic
callers and 617-801-6888 for international callers, using the pass
code 14989109. A live webcast of North American Scientific�s
conference call will be available over the Internet through its
website at www.nasmedical.com in the Investor Center. For those who
cannot listen to the live webcast, a replay of the call will be
available at the same site shortly after the call. About North
American Scientific North American Scientific is a leader in
radiation therapy in the fight against cancer. Its innovative
products provide physicians with tools for the treatment of various
types of cancers. They include Prospera� brachytherapy seeds and
SurTRAK� needles and strands used primarily in the treatment of
prostate cancer. In addition, the Company has been gaining clinical
experience with its first generation ClearPath� multi-channel
catheter breast brachytherapy devices in 2007, and intends to
launch the second generation devices in 2008. They are the only
such devices approved for both high dose and continuous release, or
low dose, radiation treatments. The devices are designed to provide
flexible, precise dose conformance and an innovative delivery
system that is intended to offer the more advanced form of
brachytherapy for the treatment of breast cancer. Please visit
www.nasmedical.com for more information. Statements included in
this release that are not historical facts may be considered
forward-looking statements that are subject to a variety of risks
and uncertainties. There are a number of important factors that
could cause actual results to differ materially from those
expressed in any forward-looking statements made by the Company
including, but not limited to, the impact of competitive products
and pricing, technological changes, changes in relationships with
strategic partners and dependence upon strategic partners for the
performance of critical activities under collaborative agreements,
the ability of the Company to successfully directly market and sell
its products, uncertainties relating to patent protection and
regulatory approval, the stable supply of appropriate isotopes,
research and development estimates, market opportunities, risks
associated with strategic opportunities or acquisitions the Company
may pursue and the risk factors included in the Company�s filings
with the Securities and Exchange Commission. Any forward-looking
statements contained in this news release speak only as of the date
of this release, and the Company undertakes no obligation to revise
or update any forward-looking statements, whether as a result of
new information, future results or otherwise.
Grafico Azioni North American Scientific (MM) (NASDAQ:NASM)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni North American Scientific (MM) (NASDAQ:NASM)
Storico
Da Giu 2023 a Giu 2024
Notizie in Tempo Reale relative a North American Scientific (MM) (NASDAQ): 0 articoli recenti
Più North American Scientific, Inc. Articoli Notizie